Urogen Pharma (NASDAQ:URGN) Announces Earnings Results, Beats Estimates By $0.20 EPS

Urogen Pharma (NASDAQ:URGN) announced its quarterly earnings results on Tuesday. The company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.20, Fidelity Earnings reports.

URGN stock traded down $1.32 during midday trading on Wednesday, hitting $26.19. The company’s stock had a trading volume of 9,958 shares, compared to its average volume of 205,985. The company has a market cap of $492.33 million, a PE ratio of -5.44 and a beta of 1.12. Urogen Pharma has a 12 month low of $20.72 and a 12 month high of $55.49. The firm’s 50-day moving average is $23.30 and its 200-day moving average is $31.78.

A number of research analysts recently issued reports on URGN shares. HC Wainwright set a $75.00 price target on Urogen Pharma and gave the company a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. restated a “hold” rating and set a $39.00 price target on shares of Urogen Pharma in a report on Wednesday. Zacks Investment Research upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, October 26th. Stifel Nicolaus set a $41.00 target price on Urogen Pharma and gave the stock a “buy” rating in a report on Sunday, October 20th. Finally, ValuEngine upgraded Urogen Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Urogen Pharma presently has an average rating of “Buy” and a consensus price target of $53.00.

In related news, CFO Peter P. Pfreundschuh sold 1,416 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $33.07, for a total value of $46,827.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 10.50% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Story: What is the yield curve?

Earnings History for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.